{"protocolSection":{"identificationModule":{"nctId":"NCT05700097","orgStudyIdInfo":{"id":"NCRC-2022-02"},"organization":{"fullName":"Beijing Tiantan Hospital","class":"OTHER"},"briefTitle":"Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy","officialTitle":"A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-Finding, Multi-center Study to Assess the Efficacy and Safety of Dengzhanxixin Injection in Patients With Acute Ischemic Stroke Receiving Reperfusion Therapy"},"statusModule":{"statusVerifiedDate":"2023-01","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-09-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-09-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2023-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-11-16","studyFirstSubmitQcDate":"2023-01-16","studyFirstPostDateStruct":{"date":"2023-01-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-01-16","lastUpdatePostDateStruct":{"date":"2023-01-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Beijing Tiantan Hospital","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"To assess the Efficacy and Safety of Dengzhanxixin Injection in Patients With Acute Ischemic Stroke Receiving Reperfusion Therapy.","detailedDescription":"To evaluate the safety and efficacy of Dengzhanxixin at different doses of 80ml/day, 40 ml/day, or placebo within 24 hours after the onset of ischemic stroke. The primary objective of this study is the proportion of subjects with excellent outcomes defined as mRS (0-1) among the three treatment groups at 90 days."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":240,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Low Dose Arm","type":"EXPERIMENTAL","description":"Dengzhanxixin injection 40ml/day, placebo 40ml/day. Dengzhanxixin injection 40ml, diluted with 250ml of 0.9% sodium chloride injection and then slowly intravenously infused once a day; placebo injection 40ml, diluted with 250ml of 0.9% sodium chloride injection and then slowly intravenously infused once a day.","interventionNames":["Drug: Dengzhanxixin Injection"]},{"label":"High Dose Arm","type":"EXPERIMENTAL","description":"Dengzhanxixin injection 80ml/day. Dengzhanxixin injection 40ml, diluted with 250ml of 0.9% sodium chloride injection, and then slowly intravenously infused twice a day.","interventionNames":["Drug: Dengzhanxixin Injection"]},{"label":"Placebo Arm","type":"PLACEBO_COMPARATOR","description":"Placebo injection 80ml/day. Placebo injection 40ml, diluted with 250ml of 0.9% sodium chloride injection, and then slowly intravenously infused twice a day.","interventionNames":["Drug: Placebo injection"]}],"interventions":[{"type":"DRUG","name":"Dengzhanxixin Injection","description":"Experimental arms for low, and high dose for the standard protocol","armGroupLabels":["High Dose Arm","Low Dose Arm"],"otherNames":["Dengzhanxixin Zhusheye"]},{"type":"DRUG","name":"Placebo injection","description":"placebo control arm for the standard protocol","armGroupLabels":["Placebo Arm"],"otherNames":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Primary Efficacy Outcome","description":"Proportion of subjects of excellent outcome defined as modified Rankin Scale (mRS) (0-1) at 90 days. mRS is a 7 grade scale from 0 to 6, where 0 is the best and 6 is the worst outcome.","timeFrame":"90 days"},{"measure":"Primary Safety Outcome","description":"Proportion of patients with adverse events at 90 days.","timeFrame":"90 days"}],"secondaryOutcomes":[{"measure":"Infarction Volume","description":"Infarction volume at 14 days compared to baseline","timeFrame":"14 days"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"National Institutes of Health Stroke Scale (NIHSS) score changes from baseline. NIHSS is 42 point scale where 0 is the best o and 42 is the worst outcome.","timeFrame":"72 hours， 7 days， 14 days， 90days"},{"measure":"Excellent functional outcome","description":"Favourable outcome rate is defined as the proportion of subjects with modified Rankin Scale (mRS) (0-1). mRS is a 7 grade scale from 0 to 6, where 0 is the best and 6 is the worst outcome.","timeFrame":"14 days"},{"measure":"Modified Rankin Scale (mRS) distribution","description":"Ordinal distribution of Modified Rankin Scale (mRS). mRS is a 7 grade scale from 0 to 6, where 0 is the best and 6 is the worst outcome.","timeFrame":"14 days， 90 days"},{"measure":"Barthel index (BI)","description":"Proportion of subjects with Global function of daily living defined as Change in Barthel index (BI) ≥ 95. BI is a 10 item scale with scores ranging from 0 to 100, where a score of 100 is the best and 0 is the worst outcome.","timeFrame":"90 days"},{"measure":"Symptomatic intracranial hemorrhage(sICH)","description":"Proportion of subjects with symptomatic intracranial hemorrhage (sICH)","timeFrame":"14 days"},{"measure":"AEs","description":"Proportion of subjects with AEs","timeFrame":"72 hours，7 days， 14 days"},{"measure":"SAEs","description":"Proportion of subjects with SAEs","timeFrame":"72 hours，7 days， 14 days，90days"}],"otherOutcomes":[{"measure":"Biomarkes","description":"The changes of serum high sensitivity C-reactive protein test (hs-CRP) level from baseline to 14 days","timeFrame":"14 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* More than or equal to 18 years old and less than 80 years old;\n* Acute ischemic stroke confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) of the head;\n* Stroke onset within 24 hours and can be treated with study drug within 24 hours of symptoms onset；\n* The patient has received or is planning to receive vascular reperfusion therapy after onset；\n* Baseline NIHSS score is ≥4 and ≤26.\n* mRS ≤1 prior onset.\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Intracranial hemorrhage: cerebral hemorrhage, subarachnoid hemorrhage, etc.;\n* The acute infarcts lesion Involvement of more than one-third of middle cerebral artery (MCA) territory on initial brain imaging;\n* Rapidly improving symptoms at the discretion of the investigator;\n* Patients who have taken Dengzhanxixin Injection，edaravone or other brain protective drugs after onset ;\n* History of intracranial hemorrhage；\n* History of severe head trauma, stroke or myocardial infarction in past 3 months;\n* Diagnosised intracranial tumor and giant intracranial aneurysm；\n* Diagnosised aortic arch dissection；\n* Undergoing major surgery within 2 weeks prior to screening; or intracranial or intraspinal surgery within 3 months prior to screening;\n* Currently accompanied by active visceral bleeding; or arterial puncture at a site that is not easy to compress hemostasis within 1 week before screening; or gastrointestinal or urinary system bleeding occurred within 3 weeks before screening;\n* Those with acute bleeding tendency, including: platelet count \\<100×109/L, combined with hemophilia, etc.; or those with partially activated thrombin time greater than 3 times the upper limit of normal;\n* Oral anticoagulants, and international normalized ratio\\>1.7 or prothrombin time\\>15s;\n* Diagnosed primary liver and kidney disease, AST or ALT (\\>2 times the ULN), serum creatinine \\>2.0mg/dL or \\>176.8µmol/L;\n* Persistent blood pressure elevation ( systolic ≥180 mmHg or diastolic ≥100 mmHg ), despite blood pressure lowering treatment;\n* Those with a history of epilepsy or epilepsy-like symptoms at the onset of stroke;\n* Complete atrioventricular block; or according to the New York Heart Association (NYHA) cardiac function class II or above; or have been hospitalized due to congestive heart failure within 6 months before screening;\n* Pregnant women, nursing mothers, or reluctant to agree taking effective contraceptive measures during the period of trial subjects;\n* Those who have other neurological diseases or disabilities or mental diseases, which may affect the efficacy evaluation of this study as judged by the investigator;\n* Those with a history of malignant tumor within 5 years before screening (if the patient has basal cell carcinoma of the skin or carcinoma in situ of the cervix and has been cured, he/she can participate in this study);\n* Those who participated in other drug/device clinical studies and used the experimental drug/device within 3 months before screening;\n* Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study。","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Yongjun Wang, M.D.","affiliation":"Beijing Tiantan Hospital, Capital Medical University, Beijing, China","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Beijing Tiantan Hospital","city":"Beijing","state":"Beijing","zip":"100070","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}